Cai Jing Wang
Search documents
建信财险副总经理张启航任职资格获核准
Cai Jing Wang· 2026-01-21 12:44
1月21日,国家金融监督管理总局宁夏监管局发布批复,核准张启航建信财产保险有限公司副总经理的 任职资格。 批复显示,建信财险应要求上述核准任职资格人员严格遵守金融监管总局有关监管规定,自本行政许可 决定作出之日起2个月内到任,并按要求及时报告到任情况。未在上述规定期限内到任的,本批复文件 失效,由决定机关办理行政许可注销手续。 建信财险应督促上述核准任职资格人员持续学习和掌握经济金融相关法律法规,牢固树立风险合规意 识,熟悉任职岗位职责,忠实勤勉履职。 (国家金融监督管理总局) ...
白银基金溢价率超50% 明天全天停盘
Cai Jing Wang· 2026-01-21 12:01
1月21日,国投瑞银基金管理有限公司发布国投白银LOFA类份额高溢价风险提示及停牌公告摘要 近期,国投瑞银白银期货证券投资基金(LOF)A类基金份额(场内简称:国投白银LOF,代码:161226)二级市场交易价格大幅高于基金份额净值,引发 重大投资风险。2026年1月20日基金份额净值为2.6095元,而1月21日收盘价达3.920元,溢价率超50%,存在明显非理性交易。为保护投资者利益,本基金于 2026年1月22日开市起停牌至收市,若1月23日溢价未有效回落,将申请盘中临时停牌或延长停牌,以警示市场风险。 截屏2026-01-21 19.13.59 本基金为上市开放式基金(LOF),投资者既可通过二级市场交易,也可按当日净值申购赎回。当前A类基金份额单笔申购上限为100.00元,基金管理人提 示该申购限额极低,高溢价不具备可持续性,后续可能进一步调整限额。目前基金运作正常,无其他应披露未披露重大信息,管理人将依法依规履行投资与 信息披露义务。 二级市场价格受基金份额净值、市场供求、系统性风险及流动性等多重因素影响,投资者若盲目追高,可能面临本金损失。基金管理人重申"买者自负"原 则,提醒投资者认真阅读《基 ...
宁波银行:2025年实现归母净利润293.33亿元,同比增长8.13%
Cai Jing Wang· 2026-01-21 11:11
1月20日,宁波银行发布2025年业绩快报。2025年,宁波银行实现营业收入719.68亿元,同比增长8.01%;实现归属于 母公司股东的净利润293.33亿元,同比增长8.13%。公司实现利息净收入531.61亿元,同比增长10.77%;实现手续费及 佣金净收入60.85亿元,同比增长30.72%,轻资本业务增长势头良好。 截至2025年末,宁波银行不良贷款余额131.47亿元,不良贷款率0.76%,较上年末持平;拨备覆盖率373.16%,拨备水 平保持充足。 截至2025年末,宁波银行贷款和垫款总额17,333.13亿元,较年初增加2,572.50亿元,增长17.43%,占总资产比重 47.77%,较年初提升0.54个百分点。 (宁波银行) 截至2025年末,宁波银行客户存款总额20,248.83亿元,较年初增加1,885.38亿元,其中活期存款新增占比70.84%,存 款付息率同比下降33BP,2025年12月当月付息率1.42%,同比下降44BP,负债成本进一步降低。 ...
周大福集团2026财年第三季度售值同比增长17.8%,中国内地零售值同比增长16.9%
Cai Jing Wang· 2026-01-21 09:42
渠道布局上,中国内地市场优化零售网络,选择性新增34个零售点、关闭264个表现欠佳零售点,净减 少230个;中国香港及中国澳门地区新增3个零售点。内地电商业务凭借双十一销售热潮及IP合作,零售 值同比增长25.3%,对内地零售值及销量贡献分别达7.4%和17.0%。国际扩张成为下一阶段增长重点, 周大福计划2026年6月前推出新店以进军国际市场,聚焦精选高端地段。 期内,中国内地直营店同店销售同比增长21.4%,加盟店同店销售同比增长26.3%,剔除钟表业务后直 营店同店销售增幅升至25.6%;中国香港及中国澳门地区同店销售同比增长14.3%,中国香港、澳门分 别上涨10.1%、31.3%。产品售价方面,中国内地计价黄金首饰平均售价升至1.1万港元,定价黄金首 饰、珠宝镶嵌首饰平均售价分别升至9500港元、8900港元;中国香港及中国澳门地区计价黄金首饰平均 售价达2.01万港元,定价黄金首饰平均售价升至8300港元,珠宝镶嵌首饰平均售价为1.75万港元。 (周大福集团财报) 1月21日,周大福集团发布截至2025年12月31日止三个月主要经营数据,集团零售值同比增长17.8%, 其中中国内地零售值同比增长1 ...
呷哺呷哺集团推子品牌“呷牛排”:主打百元起“牛排+畅吃”模式,预计三年达百店规模
Cai Jing Wang· 2026-01-21 09:05
Core Viewpoint - The company, Xiaobuxiang Group, is entering the steak market with a new sub-brand "Xiaoniupai," aiming to popularize high-quality steak dining at affordable prices, addressing a gap in the market [1] Group 1: Brand Launch and Concept - "Xiaoniupai" will open its first store on February 6 in Beijing's Changping Longde Plaza [1] - The brand focuses on "handmade Taiwanese-style thick steak" as its core offering, combined with 158 free dishes from various cuisines and afternoon tea options [1] Group 2: Menu and Pricing Strategy - The restaurant will offer a "steak + all-you-can-eat" model, where customers can pay starting from 100 yuan to enjoy steak and access to 158 types of food, including teppanyaki, barbecue, pizza, and desserts [1] - An afternoon tea option priced at 39.9 yuan will cater to diverse consumer needs, targeting exploratory diners, families, and young consumers [1] Group 3: Future Plans and Growth Strategy - The founder and chairman of Xiaobuxiang Group, He Guangqi, expressed the goal of making handmade Taiwanese-style steak culture accessible to a wider audience and establishing a national brand [1] - The company plans to optimize its operational model and service standards after the initial store launch, with a target of reaching 100 stores within three years, adjusting goals based on individual store profitability [1]
内蒙古西贝餐饮集团有限公司获A轮融资,注册资本增至约1.02亿元
Cai Jing Wang· 2026-01-21 08:47
(企查查) 1月21日,企查查显示,内蒙古西贝餐饮集团有限公司获A轮融资。投资方包括台州新荣泰投资有限公 司、呼和浩特市集体共创企业管理中心(有限合伙)、成都迅达光电有限公司等。此外,该公司注册资 本亦发生变更,由8990.2896万元增至10168.0175万元。 ...
恩威医药:2025年净利润为5650万元至6650万元,主营业务收入增长带来净利润增加
Cai Jing Wang· 2026-01-21 08:27
近日,恩威医药披露2025年度业绩预告,预计2025年归母净利润为5650万元至6650万元,同比增长50.68%至77.35%。 2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少。 (恩威医药公告) ...
西比曼生物:阿斯利康将收购GPC3装甲型CAR-T疗法在中国的剩余权益
Cai Jing Wang· 2026-01-21 08:26
Core Viewpoint - The agreement between Westaim Biopharma and AstraZeneca allows AstraZeneca to acquire 50% of Westaim's rights for the development and commercialization of C-CAR031 in China, granting AstraZeneca exclusive global rights for C-CAR031 [1] Group 1 - AstraZeneca will pay Westaim up to $630 million, which includes an upfront payment for the GPC3 project in China as well as milestone payments related to development, regulatory, and sales achievements [1] - AstraZeneca already holds the rights for the development, production, and commercialization of C-CAR031 outside of China, and Westaim remains eligible for additional milestone payments and royalties for global development [1]
呷哺呷哺集团推子品牌“呷牛排”,主打百元起“牛排+畅吃”模式,预计三年达百店规模
Cai Jing Wang· 2026-01-21 08:26
Group 1 - The core viewpoint of the article is that Xiabuxiabu Group is entering the steak market with a new sub-brand "Xiniu Steak," aiming to popularize high-quality steak dining at affordable prices [1] - The first store of "Xiniu Steak" will open on February 6 in Beijing's Changping Longde Plaza, featuring a business model centered around "handmade Taiwanese-style thick steak" along with 158 free dishes from various cuisines [1] - The restaurant offers a "steak + all-you-can-eat" format, where customers can pay starting from 100 yuan to enjoy steak and unlimited access to 158 types of food, including teppanyaki, barbecue, pizza, and desserts [1] Group 2 - "Xiniu Steak" also introduces a 39.9 yuan afternoon tea option to cater to diverse consumer needs, targeting exploratory diners, families, and young consumers [1] - The founder and chairman of Xiabuxiabu Group, He Guangqi, expressed the goal of bringing handmade Taiwanese steak culture to a wider audience and filling a market gap by promoting affordable high-end steak [1] - After the initial store launch in 2026, the company plans to focus on optimizing operational models and building organizational capabilities, with a target of reaching 100 stores within three years based on single-store profitability [1]
南侨食品:预计2025年归属净利润3626.37万至4351.64万元,将加大新品投入
Cai Jing Wang· 2026-01-21 08:26
Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a decrease of 78.39% to 81.99% compared to the previous year, primarily due to rising raw material costs and a decrease in the proportion of high-margin products [1] Group 1: Financial Performance - The projected net profit for 2025 is estimated to be between 36.26 million to 43.52 million yuan [1] - The decline in profit is attributed to increased prices of key raw materials, leading to higher production costs and a decrease in overall gross and net profit margins [1] Group 2: Raw Material Costs - Key raw materials include palm oil, soybean oil, coconut oil, and natural cream, all of which have seen significant price increases [1] - Palm oil prices have shown notable fluctuations, while coconut oil prices have reached historical highs, contributing to cost pressures [1] Group 3: Competitive Landscape - The company faces intensified industry competition, which has resulted in product price increases lagging behind raw material cost hikes, further pressuring profit levels [1] Group 4: Strategic Initiatives - The company plans to monitor raw material price trends and adjust procurement strategies dynamically to mitigate cost impacts [2] - Efforts will be made to enhance operational efficiency through process optimization, automation, and supply chain management [2] - The company aims to drive revenue growth through a dual approach of market expansion and product innovation, focusing on retail and emerging channels [2] - Product offerings will be diversified to meet various market demands, with an emphasis on upgrading to clean label and high-end products [2]